Consistent with this, it has been reported that the emergence of TIM-3+ Tregs compensates for PD-L1 blockade, and causes resistance to therapy, tumor relapse and progression in head and neck mouse cancer model [45]. This evidence concerns the gene HAVCR2 and neoplasm.